{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Humaneva Insights","title":"One trial may be enough. One uninterpretable trial is not","html":"","width":"100%","height":180,"duration":575,"description":"Episode Summary\nIn the inaugural episode of Humaneva Insights, host Patrick McManus speaks with Dr. Brandon Fletcher, Head of Medical Affairs and Cell & Gene Therapy at Kapadi, about when a single adequate and well-controlled clinical trial may be sufficient to support an FDA regulatory decision in oncology.\nA one-trial pathway is not a shortcut to a lower evidentiary standard. In immuno-oncology, the study still needs to produce evidence that is interpretable, attributable, internally credible, and clinically meaningful. Patrick and Brandon discuss when an exceptional response signal may speak for itself, why uncertainty around causality and contribution of components can still require randomization, and how early design choices determine whether a promising program reaches the application stage with evidence regulators can confidently assess.\nKey Takeaways\nOne pivotal trial may be sufficient, but it should not be interpreted as less evidence.\nWhen one study carries the weight of an entire development program, the control arm, population definition, response assessment, missing-data strategy, and endpoint attribution must be defensible from the outset.\nRegulatory strategy, estimand definition, biomarker strategy, imaging methodology, and confirmatory planning should be integrated early rather than treated as downstream activities.\nA very large and durable response may sometimes support accelerated approval in a refractory population with a well-characterized natural history and limited treatment options.\nCombination regimens, heterogeneous post-immunotherapy populations, delayed immune effects, retreatment, and investigator interpretation can make clinically impressive results difficult to attribute.\nRandomized expansion cohorts can establish the contribution of treatment components, reduce dependence on historical controls, and close evidentiary gaps before a traditional phase 3 program.\nFeatured Expert\n\nDr. Brandon Fletcher is Head of Medical Affairs and Cell...","thumbnail_url":"https://img.transistorcdn.com/VEApGY9kGCRBCWdXiyY2M4SbT8Aa9OebLNCW4IYaXZo/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS82Yzgx/ZDVhMTE4YmE1Nzcw/YjRiNTcxZDMzNjA2/YWU0MC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}